These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 28058444

  • 1. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki EM, Harris ST.
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, Mirza FM, Stolshek BS.
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [Abstract] [Full Text] [Related]

  • 4. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T, Boyanov M, Shinkov A, Petkova R, Intorcia M, Psachoulia E.
    Arch Osteoporos; 2017 Dec 21; 13(1):1. PubMed ID: 29264666
    [Abstract] [Full Text] [Related]

  • 5. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 21; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 6. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
    Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H, Kurth AA, Thomasius F, Schulte M, Intorcia M, Psachoulia E, Schmid T.
    Osteoporos Int; 2016 Oct 21; 27(10):2967-78. PubMed ID: 27172934
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ, Tsai JN, Jiang LA, Lee H.
    Bone; 2017 May 21; 98():54-58. PubMed ID: 28286299
    [Abstract] [Full Text] [Related]

  • 10. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
    Ban JK, Hao BB, McCarthy L, Guilcher SJT, Cadarette SM.
    Osteoporos Int; 2019 Sep 21; 30(9):1865-1872. PubMed ID: 31317248
    [Abstract] [Full Text] [Related]

  • 11. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA.
    Lancet; 2015 Sep 19; 386(9999):1147-55. PubMed ID: 26144908
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, Geusens P, Makras P, Resch H, Möller G, Kalouche-Khalil L, Fahrleitner-Pammer A.
    Osteoporos Int; 2015 Oct 19; 26(10):2479-89. PubMed ID: 26018090
    [Abstract] [Full Text] [Related]

  • 14. Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program.
    Papaioannou A, Khan A, Belanger A, Bensen W, Kendler D, Theoret F, Amin M, Brekke L, Erdmann M, Walker V, Adachi JD.
    Curr Med Res Opin; 2015 Oct 19; 31(7):1391-401. PubMed ID: 25993017
    [Abstract] [Full Text] [Related]

  • 15. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D, Beckett T, Kourtjian E, Messingschlager C, Sipahi R, Padley M, Stubbart J.
    Osteoporos Int; 2018 Jun 19; 29(6):1351-1357. PubMed ID: 29541794
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
    Suzuki T, Nakamura Y, Kato H.
    Mod Rheumatol; 2019 Jul 19; 29(4):676-681. PubMed ID: 30217118
    [Abstract] [Full Text] [Related]

  • 17. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
    Lin SY, Chen YM, Chen WJ, Li CY, Ku CK, Chen CH, Chien LN.
    Arch Osteoporos; 2022 Jul 15; 17(1):94. PubMed ID: 35840845
    [Abstract] [Full Text] [Related]

  • 18. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
    Ebina K, Hashimoto J, Kashii M, Hirao M, Miyama A, Nakaya H, Tsuji S, Takahi K, Tsuboi H, Okamura G, Etani Y, Takami K, Yoshikawa H.
    Mod Rheumatol; 2021 Mar 15; 31(2):485-492. PubMed ID: 32412351
    [Abstract] [Full Text] [Related]

  • 19. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C.
    Clin Drug Investig; 2013 Feb 15; 33(2):117-22. PubMed ID: 23184667
    [Abstract] [Full Text] [Related]

  • 20. Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States.
    McGrath LJ, Spangler L, Curtis JR, Ehrenstein V, Sørensen HT, Saul B, Levintow SN, Reams D, Bradbury BD, Brookhart MA.
    Pharmacoepidemiol Drug Saf; 2020 Aug 15; 29(8):854-863. PubMed ID: 32537883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.